Study #2015-0519
A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Adavosertib
Description
This pilot early phase I trial studies how adavosertib affects the tumor deoxyribonucleic acid (DNA) of patients undergoing surgery for high grade (fast growing or aggressive) ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body (advanced). Certain characteristics in the DNA of these patients may affect how well they respond to treatment. Learning how adavosertib affects DNA in tumor cells may help doctors plan effective treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC V7, Stage III Ovarian Cancer AJCC V6 and V7, Stage III Primary Peritoneal Cancer AJCC V7, Stage IIIA Fallopian Tube Cancer AJCC V7, Stage IIIA Ovarian Cancer AJCC V6 and V7, Stage IIIA Primary Peritoneal Cancer AJCC V7, Stage IIIB Fallopian Tube Cancer AJCC V7, Stage IIIB Ovarian Cancer AJCC V6 and V7, Stage IIIB Primary Peritoneal Cancer AJCC V7, Stage IIIC Fallopian Tube Cancer AJCC V7, Stage IIIC Ovarian Cancer AJCC V6 and V7, Stage IIIC Primary Peritoneal Cancer AJCC V7, Stage IV Fallopian Tube Cancer AJCC V6 and V7, Stage IV Ovarian Cancer AJCC V6 and V7, Stage IV Primary Peritoneal Cancer AJCC V7
Study phase:
Phase I (Early)
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-844-577-0738
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.